PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Symptom | |brain metastases |
| Sentences | 95 |
| PubMedID- 19951956 | Long-term survivors among breast cancer patients with brain metastases. |
| PubMedID- 25156682 | Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype. |
| PubMedID- 21209717 | The annual incidence of brain metastases in patients with breast cancer is in the range of 4-11 per 100.000 persons per year. |
| PubMedID- 26109921 | Methods: a breast cancer patient with 8 brain metastases was treated on the brain by a radical rt regimen. |
| PubMedID- 24244833 | brain metastases of invasive breast cancer are associated with 1 and 2 year survival rate of 20% and <2% respectively. |
| PubMedID- 23718256 | Methods: a retrospective database of 100 patients treated for brain metastases due to breast cancer via gamma knife radiosurgery (gks) from july 1998 through march 2009 was reviewed. |
| PubMedID- 24294457 | Gkrs has shown to be an effective and safe treatment modality for treating brain metastases of primary breast cancer. |
| PubMedID- 24740972 | After local treatment, the combination of weekly trastuzumab plus vinorelbine may be an effective alternative regimen in her-2 positive breast cancer patients with brain metastases. |
| PubMedID- 26052228 | brain metastases are common in patients with advanced breast cancer (bc), causing considerable morbidity and mortality. |
| PubMedID- 23394467 | Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases. |
| PubMedID- 26215106 | Demonstrated that among breast cancer patients with brain metastases, the patients with her2 expression had better survival compared to the patients with other molecular histologic subtypes . |
| PubMedID- 23557557 | Background: the incidence of brain metastases in patients with breast cancer is approximately 10% - 16%, and survival after diagnosis of brain metastases is usually short. |
| PubMedID- 20549816 | Background: the aim of this study was to assess the role of systemic treatment after whole-brain radiotherapy (wbrt) in immunohistochemically defined biological subsets of breast cancer patients with brain metastases. |
| PubMedID- 24350786 | This report suggests that eribulin treatment may be beneficial for breast cancer patients with brain metastases progressing after wbrt. |
| PubMedID- 23462853 | The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. |
| PubMedID- 25977884 | Lapatinib access into normal brain and brain metastases in patients with her-2 overexpressing breast cancer. |
| PubMedID- 23115660 | Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases. |
| PubMedID- 20604919 | For the first time, we have identified somatic mutations in genes related to the akt/mapk signaling pathways, such as egfr, pik3ca, kras, hras and nras, in brain metastases of breast cancer and other types of cancer. |
| PubMedID- 22333639 | A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy. |
| PubMedID- 22421776 | A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies. |
| PubMedID- 20004109 | The incidence of symptomatic brain metastases among women with metastatic breast cancer ranges from 10% to 16%. |
| PubMedID- 23667803 | (a)time to brain metastases from diagnosis of primary breast cancer according to subtype and trastuzumab administration before brain metastases development. |
| PubMedID- 23827085 | Materials and methods: breast cancer patients with known brain metastases were included in this retrospective study, if cross-sectional imaging of the brain computed tomography (ct) was available to review and her-2 and er status was known. |
| PubMedID- 23650496 | brain metastases arising from breast cancer are a burgeoning clinical problem associated with decline in quality of life, loss of independence, and poor survival 1. |
| PubMedID- 23122784 | Methods: in this single-arm phase 2, open-label, multicentre study, eligible patients had her2-positive metastatic breast cancer with brain metastases not previously treated with wbrt, capecitabine, or lapatinib. |
| PubMedID- 22516807 | Validity of three recently proposed prognostic grading indexes for breast cancer patients with radiosurgically treated brain metastases. |
| PubMedID- 24060578 | Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of rad51. |
| PubMedID- 23443093 | The related evidence has mostly been based on researche about brain metastases of breast cancer. |
| PubMedID- 23302543 | This is comparable to the median os of approximately 4 months reported in historical analyses of breast cancer patients with brain metastases . |
| PubMedID- 22700320 | brain metastases frequently occur in patients with advanced breast cancer.effective treatment strategies are therefore needed against brain metastasis from breast carcinoma. |
| PubMedID- 21540140 | Whole brain radiotherapy remains standard in the management of breast cancer patients with brain metastases. |
| PubMedID- 22820413 | Regarding her2-positive breast cancer patients with established brain metastases, lapatinib (small molecule tki) seems particularly active in association with capecitabine. |
| PubMedID- 25662600 | Consequently, the management of breast cancer patients with brain metastases clearly relies on a multidisciplinary approach, including systemic treatment. |
| PubMedID- 21160581 | Whole brain radiotherapy (wbrt) remains the standard management of breast cancer patients with brain metastases, allowing for symptomatic improvement and good local control in most patients. |
| PubMedID- 23634179 | Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach. |
| PubMedID- 24306136 | Here, we describe preclinical imaging strategies that we have used to study the development of brain metastases due to breast cancer. |
| PubMedID- 25106661 | To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. |
| PubMedID- 25893587 | Minimal research has been conducted on the risk factors for and incidence of brain metastases in women with inflammatory breast cancer (ibc). |
| PubMedID- 22132754 | Overall survival by pten status as determined by brain metastases immunohistochemistry in patients with triple-negative breast cancer. |
| PubMedID- 20525352 | Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. |
| PubMedID- 23205151 | Here, we show that this ability can be exploited to deliver both diagnostic and therapeutic nanoparticles specifically to experimental brain metastases of breast cancer. |
| PubMedID- 24176086 | Inpatient stays coded as breast cancer (c50) with brain metastases (c79.3) were selected. |
| PubMedID- 26463521 | Strategies designed to treat brain metastases of breast cancer, particularly chemotherapeutics such as irinotecan, demonstrate limited efficacy. |
| PubMedID- 23047551 | Background: the clinical course of breast cancer patients with brain metastases (bm) as only metastatic site (brain-only metastatic breast cancer (bo-mbc)) has been insufficiently explored. |
| PubMedID- 23665199 | Current standard systemic therapies for treating breast cancer patients with brain metastases are inefficient. |
Page: 1 2